InflaRx to prune headcount by 30%, curb COVID drug spending in bid to advance new favorite asset izicopan
8th January 2026 Uncategorised 0Shortly after floating a contingency plan for its asset, vilobelimab—which boasts an emergency use authorization for COVID-19 in the U.S.—Germany’s InflaRx is drafting bigger changes to its organization as it looks to cut costs and focus attention on a separate candidate under development in inflammatory and immunological conditions.
More: InflaRx to prune headcount by 30%, curb COVID drug spending in bid to advance new favorite asset izicopan
Source: fierce